Sung JJ, Barkun A, Kuipers EJ et al.; Peptic Ulcer Bleed Study Group.
Chinese University of Hong Kong, Hong Kong, People’s Republic of China.
Ann Intern Med 2009;150:455–64.
[2] Clinical trial: intravenous pantoprazole vs. ranitidine for the prevention of peptic ulcer rebleeding: a multicentre, multinational, randomized trial.
van Rensburg C, Barkun AN, Racz I et al.
University of Stellenbosch, Cape Town, South Africa.
Aliment Pharmacol Ther 2009;29:497–507.
Editor’s note: These two studies concern therapies for the prevention of peptic ulcer rebleeding. In a well-conducted international study, Sung et al. evaluated the effect of intravenous esomeprazole administered as an 80 mg bolus followed by an 8-mg/h infusion over 72 h, versus placebo, following successful endoscopic hemostasis of single gastric or duodenal ulcers with high-risk stigmata [1]. After the infusion, all patients received oral esomeprazole 40 mg/day for 27 days. The study included 767 randomized patients from 91 centers in 16 countries; three patients were excluded from analysis.